# US 5,707,968 A · Inhibition of attachment of H.influenzae to human cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,707,968 A
- Document ID: US5707968A
- Status: Granted
- Kind: A
- Application number: 08/734,792
- Filed: 1996-10-23
- Granted: 1998-01-13
- Earliest claimed: 1994-05-26
- Assignees: Abbott Laboratories
- Inventors: Pradip Mukerji; Amanda Eun-Yeong Seo; Steven Neal Anderson; Linda Ann Harvey
- Web page: https://patentgrep.com/patent/US5707968A

## CPC

- A61K 38/1709: {from mammals}
- A23L 33/19: Dairy proteins
- A61K 38/018: {from milk}
- Y10S 530/832: Milk; colostrum
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The attachment of H. influenzae to human cells, such as oropharyngeal cells, may be inhibited by native human .beta.-casein, a recombinant form of human .beta.-casein, and hydrolysates of both. The human .beta.-casein or hydrolysate may be contained in a liquid enteral nutritional product such as an infant formula. The enteral nutritional product may be used, for example, in the prevention and treatment of otitis media in infants. The human .beta.-casein or hydrolysate may also be administered as a throat spray or nasally using drops or a spray.

## Claims

### Claim 1

A method of treating H. influenzae infection in humans comprising administering, via a nasal passageway, a formulation comprising a therapeutically effective amount of at least one material selected from the group consisting of .beta.-casein isolated from human milk, a recombinant form of the .beta.-casein contained in human milk and hydrolysates of both.

### Claim 2

A method of treating H. influenzae infection in humans comprising administering an oral formulation comprising a therapeutically effective amount of at least one material selected from the group consisting .beta.-casein isolated from human milk, a recombinant form of the .beta.-casein contained in human milk and hydrolysates of both.

### Claim 3 (depends on 2)

The method of claim 2, wherein said oral formulation is a throat spray.

### Claim 4

A method of inhibiting the infection of mammalian cells by H. influenzae comprising administering, via a nasal passageway, a formulation comprising a therapeutically effective amount of at least one material selected from the group consisting of .beta.-casein isolated from human milk, a recombinant form of the .beta.-casein contained in human milk and hydrolysates of both.

### Claim 5

A method of inhibiting the infection of mammalian cells by H. influenzae comprising administering an oral formulation comprising a therapeutically effective amount of at least one material selected from the group consisting of .beta.-casein isolated from human milk, a recombinant form of the .beta.-casein contained in human milk and hydrolysates of both.

### Claim 6 (depends on 5)

The method of claim 5, wherein said oral formulation is a throat spray.